Achilles Therapeutics: Funding, Investors & Team (Oct 2026)
Achilles Therapeutics is a designer of immunotherapies planned to propose future, patient-explicit treatments to treat malignant growth. The organization's immunotherapies saddle the invulnerable framework to obliterate disease cells that target truncal growth neo-antigens and banners to the resistant framework present on the outer layer of each and every malignant growth cell, empowering researchers to target and annihilate cancers without hurting sound tissues.
Achilles Therapeutics has raised $5.1M across 2 funding rounds on record, the most recent a Grant of $4.1M announced in Jul 2022.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Achilles Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2022.
Achilles Therapeutics Funding Rounds
Achilles Therapeutics raised $1.0M in an undisclosed round announced in May 2021.
1.2 years later, a Grant of $4.1M was announced in Jul 2022.
Achilles Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Achilles Therapeutics Funding Compared to Other Biotechnology Startups
Achilles Therapeutics' latest round of $4.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Achilles Therapeutics in Biotechnology and London
Companies Similar to Achilles Therapeutics
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Achilles Therapeutics Funding FAQs
What does Achilles Therapeutics do?
Achilles Therapeutics is a designer of immunotherapies planned to propose future, patient-explicit treatments to treat malignant growth. The organization's immunotherapies saddle the invulnerable framework to obliterate disease cells that target truncal growth neo-antigens and banners to the resistant framework present on the outer layer of each and every malignant growth cell, empowering researchers to target and annihilate cancers without hurting sound tissues.
How much funding has Achilles Therapeutics raised?
Achilles Therapeutics has raised $5.1M across 2 rounds on record. The most recent is a Grant of $4.1M announced in Jul 2022.
When did Achilles Therapeutics last raise funding?
Achilles Therapeutics' most recent funding round on record is a Grant of $4.1M, announced in Jul 2022.
Who founded Achilles Therapeutics?
FundedIQ lists Charles Swanton (Founder) at Achilles Therapeutics.
Who is the CEO of Achilles Therapeutics?
Aseem Ghaghda is listed as CEO at Achilles Therapeutics.
Where is Achilles Therapeutics headquartered?
Achilles Therapeutics is based in London, England, United Kingdom.
How many employees does Achilles Therapeutics have?
Achilles Therapeutics is in the 1-10 employee band.
How does Achilles Therapeutics' funding compare to other Biotechnology startups?
Achilles Therapeutics' latest round of $4.1M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Achilles Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Achilles Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.